CMS Announces Selection Of Drugs For Third Cycle Of The Medicare Drug Price Negotiation Program

Jan 27 (Reuters) - Centers for Medicare & Medicaid Services (CMS):

• CMS ANNOUNCES SELECTION OF DRUGS FOR THE THIRD CYCLE OF THE MEDICARE DRUG PRICE NEGOTIATION PROGRAM

• CMS: DRUGS SELECTED FOR THIRD CYCLE OF MEDICARE DRUG PRICE NEGOTIATION ARE REXULTI, TRULICITY, VERZENIO, XELJANZ; XELJANZ XR AND XOLAIR

• CMS: DRUGS SELECTED FOR THIRD CYCLE OF MEDICARE DRUG PRICE NEGOTIATION ARE ENTYVIO, ERLEADA, KISQALI ,LENVIMA, ORENCIA

• CMS: SELECTED DRUGS FOR THIRD CYCLE OF MEDICARE DRUG PRICE NEGOTIATIONS ARE ANORO ELLIPTA, BIKTARVY, BOTOX; BOTOX COSMETIC, CIMZIA, COSENTYX

• CMS: DRUG TRADJENTA CHOSEN FOR RENEGOTIATION FOR THE THIRD CYCLE OF THE MEDICARE DRUG PRICE NEGOTIATION PROGRAM

• CMS-ANY NEGOTIATED & RENEGOTIATED DRUG PRICES OF SELECTED DRUGS FOR THIRD CYCLE OF MEDICARE DRUG PRICE NEGOTIATION PROGRAM TO BECOME EFFECTIVE IN 2028